4D Molecular Therapeutics Inc (NASDAQ: FDMT) — Perfil da empresa, notícias e dados financeiros
4D Molecular Therapeutics designs AAV vectors for gene therapy, targeting genetic disorders with precision and innovative treatments.
4D Molecular Therapeutics Inc
4D Molecular Therapeutics (NASDAQ:FDMT) specializes in harnessing advanced genetic engineering technologies to design targeted and proprietary AAV vectors for gene therapy. Dedicated to unlocking new treatments for various genetic disorders, the company's innovative platform aims to advance the development of gene therapy products with higher precision and effectiveness. Central to its operations are the ongoing projects that focus on addressing conditions in ophthalmology, cardiology, pulmonology, and rare diseases. 4D Molecular Therapeutics' primary objective is to create transformative gene therapeutic solutions that can lead to significant improvements in treatment outcomes for patients worldwide, reflecting its commitment to both scientific innovation and patient care.
Resumo
Operações
Produtos e/ou serviços de 4D Molecular Therapeutics Inc
- Targeted and evolved AAV vectors for genetic disorders, employing their Therapeutic Vector Evolution platform to create custom vectors.
- 4D-310, a gene therapy for Fabry disease, utilizing a customized AAV vector designed for cardiac targeting.
- 4D-125, a treatment geared towards X-Linked Retinitis Pigmentosa, devised to rectify mutations in the RPGR gene.
- 4D-110, focused on treating choroideremia, using a specific AAV vector to target and deliver therapeutic genes.
- 4D-150, developed for age-related macular degeneration and diabetic macular edema, intending to inhibit multiple VEGF isoforms.
- Pipeline expansion into additional therapeutic areas including oncology, leveraging their vector evolution platform for broader applications.
equipe executiva do 4D Molecular Therapeutics Inc
- John F. MilliganExecutive Chairman
- David H. KirnCo-Founder, President, CEO & Director
- Kristian HumerCFO and Principal Financial & Accounting Officer
- Fariborz KamalChief Technical Advisor
- Theresa JankeCo-Founder & Chief of Staff
- Julian PeiHead of Investor Relations & Corporate Finance
- Katy BarglowChief Technical Officer
- Scott P. BizilyChief Legal Officer & Corporate Secretary
- An SongChief Translational Medicine Advisor
- Noriyuki KasaharaChief Scientific Advisor
Principais indicadores financeiros
Resultados divulgados pela 4D Molecular Therapeutics Inc, em USD.
- Cap. de mercado
- 660,7 mi
- Receita (TTM)
- 92 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.6
- Dividend yield
- —
- Margem de lucro
- -194.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 85,2 mi | -159,5 mi | -140,1 mi | |
| 37 mil | -187,8 mi | -160,9 mi | |
| 20,7 mi | -112,9 mi | -100,8 mi | |
| 3,1 mi | -110 mi | -101,1 mi |